A comprehensive, evidence-based information hub for patients, families and caregivers — treatments, clinical trials, research, and community resources.
DMD is the most common severe muscular dystrophy, affecting approximately 1 in 3,500 males worldwide. This portal is updated regularly with the latest approved therapies and research developments.
What is DMD?
Duchenne Muscular Dystrophy is caused by mutations in the DMD gene (Xp21) that prevent production of functional dystrophin — a protein critical for muscle cell integrity. Muscles progressively weaken over time.
Available Treatments
Steroids (prednisone, deflazacort, vamorolone), exon-skipping therapies (eteplirsen, golodirsen, viltolarsen, casimersen), gene therapy (Elevidys), and givinostat — approved in 2024.
Clinical Trials
Dozens of active trials worldwide — CRISPR editing, next-generation gene therapy, novel exon skipping. Several trials with patient registries open globally.
About Duchenne Muscular Dystrophy
Genetics, mechanism, and diagnosis
The Dystrophin Gene
DMD is caused by mutations in the DMD gene on the X chromosome (Xp21) — the largest gene in the human genome with 79 exons. Mutations (deletions, duplications, point mutations) disrupt the reading frame, preventing production of functional dystrophin protein.
Who Is Affected
DMD is X-linked recessive. It primarily affects males (1 in 3,500), while females are usually carriers. Rarely, females with Turner syndrome (45,X) or unfavorable X-inactivation may also be symptomatic.
First Symptoms
Symptoms typically appear between ages 2–5: delays in walking, frequent falls, difficulty climbing stairs or rising from the floor (Gowers' sign), calf enlargement (pseudohypertrophy), and elevated creatine kinase levels.
Diagnosis typically begins with a blood test showing markedly elevated creatine kinase (CK) levels — often 10–100 times normal. This is followed by genetic testing (NGS or MLPA) to identify the specific mutation. In some cases, muscle biopsy (showing absent dystrophin on immunostaining) is used for confirmation. Newborn screening for DMD has been introduced in some US states and is expanding globally.
DMD progresses in stages: early ambulatory (ages 2–7), late ambulatory (ages 7–12), early non-ambulatory (teens), and late non-ambulatory (adulthood). Most boys lose independent walking by age 10–12. As the disease progresses, respiratory muscles and cardiac muscle become involved. With modern care, many patients now survive into their 30s and beyond.
BMD is caused by in-frame DMD mutations that allow production of a shorter but partially functional dystrophin. BMD is milder than DMD — some patients walk into adulthood. The exon-skipping concept is based on converting DMD-type mutations into BMD-like mutations by skipping specific exons to restore the reading frame.
The heart muscle is also dystrophin-dependent. Most DMD patients develop dilated cardiomyopathy by adolescence. Cardiac monitoring (echocardiogram, MRI) and prophylactic cardiac medications (ACE inhibitors, beta-blockers) are standard of care. Respiratory monitoring and timely initiation of non-invasive ventilation (BiPAP/ventilator) are critical for survival.
Treatments
Approved therapies and medications
Corticosteroids — Standard of Care
Corticosteroids are the backbone of DMD treatment. They slow disease progression by reducing inflammation and preserving muscle function. Treatment typically begins at ages 4–5, when motor function peaks.
| Medication | Dosing | Key Notes |
|---|---|---|
| Prednisone | 0.75 mg/kg/day daily | Most widely used globally; long safety record |
| Deflazacort (Emflaza) | 0.9 mg/kg/day daily | FDA-approved 2017; less weight gain than prednisone; available in US and select countries |
| Vamorolone (Agamree) | 6 mg/kg/day daily | FDA-approved October 2023; dissociative steroid with fewer side effects; improved bone safety profile |
Important: Side Effect Monitoring
All corticosteroids carry risks: weight gain, behavioral changes, bone density loss, cataracts, and growth effects. Regular monitoring by a multidisciplinary team is essential. Never stop steroids abruptly — taper under physician supervision.
Exon Skipping — Mutation-Specific Therapy
Exon skipping uses antisense oligonucleotides (ASOs) to "skip" specific exons during pre-mRNA splicing, restoring the reading frame and enabling production of a shorter but partially functional dystrophin — similar to the milder BMD protein. Each therapy targets specific exon mutations and is only effective for patients with those mutations.
| Drug | Target Exon | Brand | FDA Approval |
|---|---|---|---|
| Eteplirsen | Exon 51 | Exondys 51 | 2016 (accelerated) |
| Golodirsen | Exon 53 | Vyondys 53 | 2019 (accelerated) |
| Viltolarsen | Exon 53 | Viltepso | 2020 (accelerated) |
| Casimersen | Exon 45 | Amondys 45 | 2021 (accelerated) |
Eligibility Check
Only ~13% of DMD patients are eligible for exon 51 skipping, ~8% for exon 53, ~9% for exon 45. Genetic testing must confirm the specific exon deletion before considering these therapies. Contact PPMD's newborn screening and genetic counseling programs for eligibility assessment.
Elevidys (Delandistrogene Moxeparvovec) — First Gene Therapy for DMD
Elevidys delivers a shortened version of the dystrophin gene (micro-dystrophin) via an AAV rh74 vector. FDA-approved in June 2023 (accelerated) and expanded in June 2024 for patients ages 4 and older who are ambulatory. Price: approximately $3.2 million per treatment.
Black Box Warning — 2025 Update
In 2025, the FDA added a black box warning to Elevidys regarding serious immune-mediated myositis reactions following treatment. Patients must be monitored closely in the weeks following infusion. The FDA also required additional confirmatory trial data from Sarepta Therapeutics.
Patients must be 4 years of age or older, ambulatory (able to walk), and must not have pre-existing antibodies to the AAVrh74 vector. Patients with certain immune conditions or prior gene therapy are excluded. A comprehensive pre-treatment screening is required at a specialized DMD center.
The full-length dystrophin gene (2.4 million base pairs) is too large for AAV delivery. Elevidys uses a shortened construct (micro-dystrophin) that retains key functional domains of the protein. While not identical to full-length dystrophin, micro-dystrophin can partially stabilize the muscle membrane and reduce damage during contraction.
Givinostat (Duvyzat)
FDA-approved March 2024 for patients 6 and older. A histone deacetylase (HDAC) inhibitor that reduces fibrosis and inflammation in muscle tissue. Taken orally, twice daily with food. Effective regardless of specific mutation type.
Cardiac Medications
ACE inhibitors (enalapril, lisinopril) and beta-blockers (carvedilol, metoprolol) are recommended to protect the heart, often started prophylactically at ages 10–12 even before cardiac symptoms appear. Eplerenone may be added as cardiomyopathy progresses.
Bone Health
Long-term steroid use reduces bone density. Calcium and vitamin D supplementation are standard. Bisphosphonates (zoledronic acid) may be prescribed if vertebral fractures occur. Regular DXA scans to monitor bone density are recommended.
Questions to Ask Your DMD Specialist
Which treatments am I genetically eligible for? When should we start steroids, and which type? Should we begin cardiac medications prophylactically? Is there an active clinical trial I qualify for? What is the cardiac and respiratory monitoring schedule?
Clinical Trials
Active research studies and how to participate
SGT-003 — Next-Generation Gene Therapy
Phase 1/2 trial (INSPIRE DUCHENNE). SGT-003 uses a novel AAVhSC17 vector with a new micro-dystrophin construct. Early results (2024) show robust expression. Enrollment open at major US and EU sites.
GNT-0004
European gene therapy program using an AAV9 vector delivering a shortened dystrophin construct. Phase 1/2 studies in France and EU sites. Funded in part by the French Muscular Dystrophy Association (AFM-Téléthon).
RGX-202
Phase 1/2 AFFINITY DUCHENNE trial. RGX-202 delivers a microdystrophin construct via AAVrh74 vector. Sites across the US and EU. Enrollment for ambulatory boys ages 4 and older.
Program Halted (2023)
Pfizer's fordadistrogene movaparvovec program was halted in 2023 following a patient death in clinical trials. This underscores the critical importance of safety monitoring in gene therapy programs.
CRISPR/Cas9 — Editing Out the Mutation
CRISPR-based approaches aim to permanently correct or delete the disease-causing mutation from the genome, rather than introducing a new gene. This could provide a one-time permanent fix — but delivery to all muscles remains a major challenge.
PBGENE-DMD
Uses prime editing technology (a next-generation CRISPR approach) to precisely correct DMD mutations without double-strand DNA breaks. IND application filed. Phase 1 trial expected to open 2025–2026.
FORCE Exon 51 & Del-Zota
Dyne's FORCE platform delivers ASOs conjugated to a muscle-targeting antibody fragment (ITGA7), dramatically improving delivery to muscle tissue. Phase 2/3 trials underway for exon 51 skipping. Del-Zota targets exon 44.
WVE-N531 (Exon 53)
A next-generation stereopure ASO for exon 53 skipping. Phase 2 FORWARD-53 trial shows higher dystrophin production than first-generation exon-53 drugs. Monthly dosing schedule.
Global Trial Access & Leading DMD Centers
DMD trials are conducted at specialized multidisciplinary centers across multiple countries. Most trials list sites at ClinicalTrials.gov. Key international centers include:
| Center | Country | Known Focus |
|---|---|---|
| Nationwide Children's Hospital (NCH) | USA | Gene therapy trials, neuromuscular program, TREAT-NMD |
| Great Ormond Street Hospital (GOSH) | UK | Pediatric DMD research, EU gene therapy trials |
| Boston Children's Hospital | USA | Multidisciplinary DMD care, cardiac research |
| Hospital for Sick Children (SickKids) | Canada | Corticosteroid trials, registry, respiratory care |
| Radboud University Medical Centre | Netherlands | Exon-skipping pioneering research (van Ommen lab) |
| Institut de Myologie (Paris) | France | Gene therapy (Genethon), AFM-Téléthon programs |
How to Find Trials
Use ClinicalTrials.gov (search "Duchenne") or PPMD's clinical trial finder at parentprojectmd.org. The TREAT-NMD network maintains a global patient registry that connects patients to trials. NORD also maintains a registry for rare diseases including DMD.
Stop Codon Readthrough
Ataluren (PTC124) is approved in some EU countries for DMD patients with nonsense mutations (~13% of all DMD). It allows ribosomes to read through premature stop codons. Multiple confirmatory trials are ongoing.
Utrophin Upregulation
Utrophin is a naturally occurring protein similar to dystrophin. Ezutromid and other utrophin modulators aim to upregulate utrophin to compensate for dystrophin deficiency. Phase 2 trials ongoing.
Cardiac-Specific Trials
Several trials focus specifically on DMD cardiomyopathy, including gene therapy vectors targeting the heart and novel cardioprotective medications. The Cooperative International Neuromuscular Research Group (CINRG) runs longitudinal cardiac studies.
Research Highlights
Latest discoveries and scientific developments
Givinostat (Duvyzat) — FDA Approval
In March 2024, the FDA approved givinostat (Duvyzat, by Italfarmaco) for DMD — the first non-mutation-specific drug approved for DMD in the US. The Phase 3 trial showed significant slowing of muscle deterioration across all DMD mutation types.
Elevidys Expanded Approval
Sarepta Therapeutics received expanded FDA approval in June 2024, making Elevidys available to all ambulatory DMD patients ages 4 and older (previously limited to ages 4–5). This dramatically increased the eligible patient population.
Cardiac Gene Therapy Research
Multiple research groups published data on AAV-mediated cardiac gene therapy in DMD mouse and dog models, showing restoration of cardiac function. Human cardiac-focused gene therapy trials are in planning stages.
Newborn Screening Programs
Several US states (including New York and Ohio) added DMD to newborn screening panels. Early detection (by CK levels) allows families to begin care planning, access trials, and start steroid therapy at the optimal developmental window.
Exoskeleton and Assistive Robotics
Clinical studies of powered exoskeletons (EksoNR, ReWalk, Ekso Indego) in DMD demonstrate sustained ambulation beyond natural walking loss. Some centers now integrate exoskeleton therapy into standard DMD physiotherapy programs.
Physiotherapy & Rehabilitation
Movement, function, and quality of life
Why Physiotherapy Is Essential
Physiotherapy in DMD aims to maintain range of motion, delay contractures, support respiratory function, and maximize functional independence at every stage of the disease. It should be tailored to the patient's current motor level (ambulatory vs. non-ambulatory).
Ambulatory Phase
Gentle stretching, hydrotherapy, low-impact exercise (swimming, cycling), and ankle-foot orthoses (AFOs) to prevent equinus contracture. Avoid eccentric exercises (downhill walking, heavy lifting) that increase muscle damage.
Non-Ambulatory Phase
Posture management, spinal alignment, standing programs (standing frames/standers), upper limb function preservation, powered wheelchair optimization. Scoliosis monitoring (Cobb angle) every 6–12 months.
Respiratory Physiotherapy
Lung volume recruitment (LVR/breath stacking), manually assisted cough techniques, mechanical insufflation-exsufflation (CoughAssist), and monitoring of FVC (forced vital capacity) every 6 months from age 5.
Night splints (ankle-foot orthoses worn during sleep) help maintain ankle dorsiflexion and delay development of calf contractures. Knee-ankle-foot orthoses (KAFOs) may extend the ambulatory period. Custom seating and spinal supports are essential once wheelchair use begins.
Warm-water pool therapy (32–34°C) is particularly beneficial in DMD. The buoyancy reduces load on weakened muscles, allowing movement that is impossible on land. Aquatic therapy can include walking, range-of-motion exercises, and recreational swimming. Safety protocols for pool entry/exit and emergency procedures are essential.
Modern powered wheelchairs offer tilt-in-space, recline, and stand functions. Choosing the right chair early (often before full loss of ambulation) allows skill building and reduces fatigue. Integration with home automation (voice control, smart home) can dramatically increase independence. Eye-gaze and head-tracking systems support communication and device control.
Lifestyle
Nutrition, mental health, education, and technology
Nutritional Considerations in DMD
Boys with DMD face dual nutritional challenges: steroid-induced weight gain in early years, and risk of malnutrition as swallowing difficulties (dysphagia) develop in later stages. Regular dietitian involvement is recommended.
Anti-Inflammatory Diet
A Mediterranean-style diet rich in omega-3 fatty acids (fish, walnuts, flaxseed), vegetables, and whole grains may support muscle health and counteract steroid-related metabolic effects. Vitamin D and calcium supplementation is essential on steroids.
Weight Management
Steroid therapy significantly increases appetite and weight gain. Maintaining healthy weight is important to preserve ambulatory function. Structured meal plans, low-glycemic foods, and avoiding excessive caloric intake help manage steroid-related obesity.
Dysphagia & Swallowing
Swallowing difficulties may develop as disease progresses. Speech-language pathologist (SLP) assessment for safe swallowing, modified food textures (IDDSI framework), and in severe cases gastrostomy (G-tube) or PEG tube placement for nutritional support.
Mental Health in DMD
DMD affects not only physical function but also psychological well-being. Higher rates of anxiety, depression, ADHD, and autism spectrum features have been documented in DMD. Early neuropsychological assessment and support are part of comprehensive DMD care.
Neurodevelopmental Profile
The dystrophin protein is expressed in the brain (Dp71 isoform). Cognitive differences, learning disabilities, and attention difficulties are more common in DMD. Neuropsychological evaluation helps identify strengths and develop educational accommodations.
Peer Support & Community
PPMD's online community, MDA's summer camps, and CureDuchenne's family events provide vital peer connections. Sibling support programs (for brothers/sisters of affected boys) are also available through national organizations.
Transition to Adulthood
Transition planning should begin by age 14: planning for independent living, higher education or vocational training, adult medical care transfer, social security/disability benefits enrollment, and relationship and sexuality counseling.
Educational Rights
In the US, the Individuals with Disabilities Education Act (IDEA) guarantees an Individualized Education Program (IEP) for children with DMD. In the UK, the Education, Health and Care Plan (EHC) provides equivalent protections. Similar frameworks exist in Canada, Australia, and EU countries.
Assistive Technology in Education
Voice-to-text software, adaptive keyboards, tablet-based writing aids, and remote learning tools support academic participation. Many schools now offer hybrid or distance learning options that benefit students with mobility limitations.
Higher Education
Many young adults with DMD attend university and pursue professional careers. Disability services offices provide accommodations (extended exam time, accessible housing, personal assistants). Organizations like PPMD offer scholarship programs for DMD patients and siblings.
Gaming & Digital Life
Many young men with DMD are enthusiastic gamers. Adaptive controllers (Xbox Adaptive Controller, Logitech Adaptive Gaming Kit), eye-tracking gaming interfaces, and head-mounted controls enable full gaming participation. Gaming communities provide important social connection.
Smart Home Integration
Voice-controlled smart home systems (Alexa, Google Home, Apple HomeKit), smart lighting, motorized beds, automated doors, and connected wheelchairs dramatically increase independence. Many local disability organizations offer smart home setup assistance.
Health Monitoring Apps
Wearable health monitors (heart rate, oxygen saturation), spirometry apps, and telemedicine platforms allow remote monitoring by DMD specialists. Apps like MOVR (from PPMD) enable patient-reported outcome tracking at home.
Psychological Support
For patients, families, and caregivers
For the Child / Young Person
Child psychologists experienced in chronic illness can help with anxiety, depression, body image, school challenges, and identity development. Cognitive-behavioral therapy (CBT) is effective for managing DMD-related anxiety and depression.
For Parents & Families
Parental grief, burnout, and anxiety are common. Organizations like PPMD, MDA, and CureDuchenne offer family support groups, online forums, and professional counseling referrals. Parent-to-parent matching programs connect newly diagnosed families with experienced ones.
For Caregivers
Caregiver fatigue and secondary trauma are real. Respite care programs, caregiver support groups, and self-care planning are essential. Many national muscular dystrophy organizations offer caregiver support services and information on respite care funding.
Multidisciplinary Psychological Care
Leading DMD centers integrate psychological and social work support directly into the multidisciplinary team. Palliative care consultation (focused on quality of life, not end of life) should begin early and continue throughout the disease course. Advance care planning discussions, though difficult, empower families and ensure that medical decisions align with personal values.
Siblings of boys with DMD may experience feelings of guilt, neglect, resentment, or sadness. Dedicated sibling support programs are available through MDA, PPMD, and many hospital-based DMD programs. School counselors should also be informed to provide additional support.
Pediatric palliative care does not mean giving up hope — it means maximizing quality of life at every stage. Palliative care teams help families discuss ventilation decisions, hospitalization preferences, and personal goals. These conversations are best had proactively, not during a crisis. Many families report that early palliative care engagement leads to better outcomes and less regret.
Stories of Courage
Voices from the DMD community
Darius Weems
Darius had DMD and became famous through the documentary "Darius Goes West" (2007), in which his friends took him on a road trip across the US. The film raised over $3 million for DMD research and became a symbol of joy and friendship in the face of progressive illness. Darius passed away in 2016 at age 27.
Mats Steen — "Ibelin"
Mats was a Norwegian young man with DMD who lived much of his life through the online game World of Warcraft, where he created a beloved character, Ibelin. After his death at 25, his parents discovered the deep friendships and community he had built online. The Netflix documentary "The Remarkable Life of Ibelin" (2024) went on to win an Oscar, shining a light on the power of digital connection for those with disabilities.
Jake Marrazzo
Jake was diagnosed with DMD at age 4, but went on to become a high school football team manager, motivational speaker, and advocate for DMD research. His story, featured in Sports Illustrated, inspired a broader conversation about inclusion, potential, and redefining what it means to participate in sports.
The DMD Community is Worldwide
DMD families, advocates, and researchers form a passionate global community. PPMD's annual conference, CureDuchenne's HOPE events, and MDA's conferences bring hundreds of families together each year. Online communities (Facebook groups, Discord servers, Reddit) provide 24/7 peer support across time zones.
Books & Media
Films, books, and podcasts about DMD
Children's Books
"My Brother Dylan" — A story for young children about a brother with DMD. "Wheels & Wings" — An illustrated book exploring life with a wheelchair. These books help siblings and classmates understand DMD in age-appropriate ways.
Films & Documentaries
"Darius Goes West" (2007) — Road trip documentary and DMD fundraising landmark. "The Remarkable Life of Ibelin" (2024, Netflix) — Oscar-winning documentary about Mats Steen and his online world. Both are widely used in DMD awareness campaigns.
Podcasts
"Decode Duchenne" by PPMD — covers clinical updates, research news, and family stories. "Muscular Dystrophy Podcast" by MDA — broader NMD coverage including DMD. "The DMD Podcast" — parent and patient perspectives on living with Duchenne.
7-Step Action Plan
A roadmap from diagnosis
Confirm the Genetic Diagnosis
Ensure full genetic sequencing (NGS panel or MLPA) to identify the exact mutation, exon(s) affected, and reading frame impact. This determines treatment eligibility (exon skipping, gene therapy, ataluren). Get a second opinion at a specialized DMD center if needed.
Build a Multidisciplinary Care Team
A comprehensive DMD team includes: pediatric neurologist/neuromuscular specialist, cardiologist, pulmonologist, physiotherapist, occupational therapist, speech-language pathologist, dietitian, psychologist, and social worker. Seek care at an MDA Care Center or equivalent specialized DMD center.
Start Corticosteroid Therapy at the Right Time
Corticosteroids are typically started when motor function plateaus (usually ages 4–6). Discuss with your neurologist which steroid (prednisone, deflazacort, or vamorolone) and which dosing schedule is most appropriate. Monitor for side effects from the start.
Start Cardiac and Respiratory Monitoring
Echocardiogram and ECG every 1–2 years (annual after age 10). Pulmonary function tests (FVC, PEF, SNIP) every 6 months from age 5. Early initiation of ACE inhibitors and beta-blockers if cardiomyopathy is detected. Plan for non-invasive ventilation when FVC drops below 50%.
Check Eligibility for Mutation-Specific Therapies
Based on the confirmed genetic mutation, assess eligibility for exon-skipping drugs (Exondys 51, Vyondys 53, Viltepso, Amondys 45), gene therapy (Elevidys), givinostat (Duvyzat), or ataluren (if nonsense mutation). Update assessment whenever new therapies are approved.
Connect with the Community & Find Trials
Register with PPMD, MDA, TREAT-NMD, and the Duchenne Registry. Join a support group. Search ClinicalTrials.gov for active trials matching your mutation. Consider enrolling in natural history studies which provide care and contribute to future treatment approvals.
Plan for the Future — Early and Continuously
Address school accommodations, physical adaptations at home, transition planning from pediatric to adult care, financial planning (special needs trusts, ABLE accounts in the US), and advance care planning. PPMD's "Certified Duchenne Care Center" program helps ensure standardized, comprehensive care.
Resources
Organizations, registries, and databases
International Organizations
PPMD (Parent Project Muscular Dystrophy) — parentprojectmd.org
CureDuchenne — cureduchenne.org
MDA (Muscular Dystrophy Association) — mda.org
World Duchenne Organization — worldduchenne.org
TREAT-NMD — treat-nmd.eu
AFM-Téléthon (France) — afm-telethon.fr
Leading DMD Centers
Nationwide Children's Hospital — Columbus, Ohio
Great Ormond Street Hospital — London, UK
Boston Children's Hospital — Boston, USA
Hospital for Sick Children (SickKids) — Toronto, Canada
Institut de Myologie — Paris, France
MDA Certified Care Centers — mda.org/care/care-centers
Research & Trial Databases
ClinicalTrials.gov — Search: "Duchenne Muscular Dystrophy"
Duchenne Registry — duchenneregistry.org (patient self-reported)
TREAT-NMD Registry — treat-nmd.eu/dmd/registry
PubMed — ncbi.nlm.nih.gov/pubmed
Neuromuscular Disease Center — neuromuscular.wustl.edu
NORD — rarediseases.org
Was this information helpful?
CarePedia is a free resource for rare disease families. We update our portals regularly with the latest research and treatments.